Filtered By:
Specialty: Consumer Health News
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 55 results found since Jan 2013.
Cinnamon May Slow Progression To Type 2 Diabetes, Boston Study Finds
(CNN) — Cinnamon may improve blood sugar control in people with a condition known as prediabetes and may slow the progression to type 2 diabetes, according to a new pilot study of 51 people with elevated blood sugars.
“We are looking for safe, durable and cost-effective approaches to reduce the progression from prediabetes to type 2 diabetes,” said study author Dr. Giulio Romeo, a staff physician at Boston’s Joslin Diabetes Center and the division of endocrinology at Beth Israel Deaconess Medical Center. The study published Tuesday in the Journal of the Endocrine Society.
“Our 12-week study sh...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 21, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Cinnamon CNN Diabetes Source Type: news
AstraZeneca's heart drug gets FDA nod
AstraZeneca Plc said on Monday the U.S. Food and Drug Administration has approved its drug for reducing the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.
Source: Reuters: Health - June 1, 2020 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Approves New Drug For Migraine Sufferers
(CNN) — The US Food and Drug Administration on Monday announced the approval of a drug called ubrogepant for the acute treatment of migraine, which could be a new option for people who can’t take or don’t respond to migraine medications currently on the market.
The drug will be sold under the name Ubrelvy by the pharmaceutical company Allergan. It is considered effective for migraine with or without aura, referring to the sensory or visual disturbances that occur among roughly a third of migraine sufferers.
“Ubrelvy represents an important new option for the acute treatment of migraine in adults, as...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 24, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston FDA Migraines Source Type: news
Two New Drugs Help Relieve Sickle-Cell Disease. But Who Will Pay?
Adakveo and Oxbryta could be revolutionary treatments, but each costs about $100,000 per year and must be taken for life.
Source: NYT Health - December 7, 2019 Category: Consumer Health News Authors: Gina Kolata Tags: Drugs (Pharmaceuticals) Health Insurance and Managed Care Sickle Cell Anemia Prices (Fares, Fees and Rates) Stroke Clinical Trials Hemoglobin Food and Drug Administration Novartis AG Global Blood Therapeutics Source Type: news
New Drug To Treat Migraines Shows Promise
(CNN) — A new drug to treat migraines has shown promise in a large-scale clinical trial, offering hope to people unable to use current treatment options.
The drug, ubrogepant, showed greater rates of pain and symptom relief from migraine compared to a placebo, with more than 20% of participants given the drug reporting to be pain-free within two hours and more than 34% relieved of the most bothersome symptoms linked to migraine, which include light and noise sensitivity. This is compared to 14% and 27%, respectively, from the placebo.
“Having ubrogepant as a potential new medication for the acute treatment of m...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Migraines Source Type: news
‘We’re Not As Healthy As We Should Be.’ Fitbit CEO James Park Discusses New AFib Detection Partnership With Bristol-Myers Squibb-Pfizer
“We’re not as healthy as we should be.”
That’s what Fitbit CEO and co-founder James Park said at Thursday’s TIME 100 Health Summit, where MSNBC anchor Stephanie Ruhle interviewed him about the company’s future in the health care space, the impact of wearables and just how active Fitbit’s 30 million active users really are.
Ruhle talked with Park about Fitbit’s position as one of the first major wearables company to have gone public, one that led the charge in terms of mass market adoption but has lost ground to competitors offering more advanced wearable devices, as well as ...
Source: TIME: Health - October 17, 2019 Category: Consumer Health News Authors: Patrick Lucas Austin Tags: Uncategorized fitness HealthSummit19 technology Source Type: news
Novartis ’ Spinal Drug Gets FDA Approval, $2 Million Price Tag
(CNN) — The US Food and Drug Administration approved a treatment Friday for a genetic disease called spinal muscular atrophy that causes infants’ muscles to waste away, potentially killing them before age 2.
And then came the price tag: $2.125 million for a one-time treatment.
The gene therapy, called Zolgensma, will be marketed by AveXis, whose parent company is Novartis.
“Today’s approval marks another milestone in the transformational power of gene and cell therapies to treat a wide range of diseases,” Dr. Ned Sharpless, the FDA’s acting commissioner, said in a statement Friday. ̶...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 24, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Novartis Source Type: news
FDA approves expanded label for Regeneron/Sanofi's cholesterol drug
The U.S. Food and Drug Administration on Friday approved Regeneron Pharmaceuticals Inc's cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
Source: Reuters: Health - April 27, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
How the first postpartum depression drug works
This week the Food and Drug Administration approved the first treatment specifically targeting postpartum depression, a condition that can impact women following childbirth, sometimes even starting during pregnancy. Symptoms can include sadness, loss of energy and feelings of guilt and worthlessness. Dr. David Agus joins "CBS This Morning: Saturday" to discuss how the new drug works and how a new personalized video game can help stroke victims.
Source: Health News: CBSNews.com - March 23, 2019 Category: Consumer Health News Source Type: news
Aspirin Lowers Your Chances of a Heart Attack. But It ’s Not Safe for Everyone, a New Study Says
As medications go, aspirin is often considered a wonder drug. Its pain-relieving, inflammation-taming powers can treat headaches, minor aches and pains and even lower the risk of heart disease, stroke and possibly even dementia.
But all of those benefits may come at a price, according to the latest study to analyze aspirin’s risks and benefits, especially for people who take the drug as a way to prevent having a first heart event. In a study published in JAMA, researchers led by Dr. Sean Zheng at King’s College London found that the risks of aspirin — primarily of bleeding in the stomach and intestinal tr...
Source: TIME: Health - January 23, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthytime Heart Disease Source Type: news
Aspirin Lowers Your Chances of a Heart Attack. But It ’s Not Safe for Everyone
As medications go, aspirin is often considered a wonder drug. Its pain-reliving, inflammation-taming powers can treat headaches, minor aches and pains and even lower the risk of heart disease, stroke and possibly even dementia.
But all of those benefits may come at a price, according to the latest study to analyze aspirin’s risks and benefits, especially for people who take the drug as a way to prevent having a first heart event. In a study published in JAMA, researchers led by Dr. Sean Zheng at King’s College London found that the risks of aspirin — primarily of bleeding in the stomach and intestinal tra...
Source: TIME: Health - January 23, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthytime Heart Disease Source Type: news
Prescription Doses of Fish Oil May Lower Heart Attack and Stroke Risk
Omega-3 fatty acids, abundant in fish oil, are known to be good for the heart. Studies have shown that people who eat more fish rich in these fats have lower rates of heart problems and less risk of dying from heart disease compared to those who eat less. Those data have fueled a booming business in over-the-counter fish oil supplements.
In a new study published in the New England Journal of Medicine, and presented at the American Heart Association annual meeting, researchers report that a highly purified version of omega-3 fats, called icosapent ethyl, can lower the risk of a number of heart-related events, including hear...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthytime Heart Disease omega-3 Source Type: news
FDA Approves First Blood Test to Help Diagnose Brain Injuries
(CHICAGO) — The first blood test to help doctors diagnose traumatic brain injuries has won U.S. government approval.
The move means Banyan Biomarkers can commercialize its test, giving the company an early lead in the biotech industry’s race to find a way to diagnose concussions.
The test doesn’t detect concussions and the approval won’t immediately change how patients with suspected concussions or other brain trauma are treated. But Wednesday’s green light by the Food and Drug Administration “is a big deal because then it opens the door and accelerates technology,” said Michael Mc...
Source: TIME: Health - February 15, 2018 Category: Consumer Health News Authors: Lindsey Tanner / AP Tags: Uncategorized APH healthytime medicine onetime Source Type: news
FDA clears Novo Nordisk's diabetes drug to reduce cardiovascular risk
(Reuters) - Novo Nordisk said on Friday the U.S. Food and Drug Administration (FDA) approved an expanded use of its diabetes drug to reduce the risk of cardiovascular events such as heart attack and stroke.
Source: Reuters: Health - August 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Rejects Eagle Pharmaceuticals ' Heat Stroke Treatment FDA Rejects Eagle Pharmaceuticals ' Heat Stroke Treatment
Eagle Pharmaceuticals Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its drug Ryanodex (dantrolene sodium) to treat heat stroke and requested an additional clinical trial, sending its shares down 20 percent.Reuters Health Information
Source: Medscape Medical News Headlines - July 28, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
